Monte Rosa Therapeutics annual working capital
2020
2021
2022
2023
2024
2025
Monte Rosa Therapeutics Working Capital Growth & History (GLUE)
Monte Rosa Therapeutics's working capital was $329.0M for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $329.0M | $108.5M | +49.20% |
| 2024 | 2024-12-31 | $220.5M | $30.9M | +16.28% |
| 2023 | 2023-12-31 | $189.6M | −$60.7M | −24.25% |
| 2022 | 2022-12-31 | $250.3M | −$81.7M | −24.61% |
| 2021 | 2021-12-31 | $332.0M | $317.7M | +2219.28% |
| 2020 | 2020-12-31 | $14.3M | — | — |
Monte Rosa Therapeutics quarterly working capital
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $571.7M | $314.1M | +121.94% |
| Q1 2026 | 2026-03-31 | $606.5M | $333.4M | +122.11% |
| Q4 2025 | 2025-12-31 | $329.0M | $108.5M | +49.20% |
| Q3 2025 | 2025-09-30 | $340.4M | $130.8M | +62.42% |
| Q2 2025 | 2025-06-30 | $257.6M | $22.1M | +9.37% |
| Q1 2025 | 2025-03-31 | $273.1M | $115.3M | +73.11% |
| Q4 2024 | 2024-12-31 | $220.5M | $30.9M | +16.28% |
| Q3 2024 | 2024-09-30 | $209.6M | $49.3M | +30.73% |
| Q2 2024 | 2024-06-30 | $235.5M | $46.5M | +24.62% |
| Q1 2024 | 2024-03-31 | $157.7M | −$62.3M | −28.31% |
| Q4 2023 | 2023-12-31 | $189.6M | −$60.7M | −24.25% |
| Q3 2023 | 2023-09-30 | $160.3M | −$113.1M | −41.38% |
| Q2 2023 | 2023-06-30 | $189.0M | −$93.3M | −33.04% |
| Q1 2023 | 2023-03-31 | $220.0M | −$87.8M | −28.53% |
| Q4 2022 | 2022-12-31 | $250.3M | −$81.7M | −24.61% |
| Q3 2022 | 2022-09-30 | $273.4M | −$84.3M | −23.57% |
| Q2 2022 | 2022-06-30 | $282.3M | −$65.2M | −18.77% |
| Q1 2022 | 2022-03-31 | $307.9M | — | — |
| Q4 2021 | 2021-12-31 | $332.0M | $317.7M | +2219.28% |
| Q3 2021 | 2021-09-30 | $357.8M | — | — |
| Q2 2021 | 2021-06-30 | $347.5M | — | — |
| Q4 2020 | 2020-12-31 | $14.3M | — | — |
Monte Rosa Therapeutics working capital trends
Over the last five fiscal years, Monte Rosa Therapeutics's working capital increased from $14.3M to $329.0M, a change of $314.7M. The latest reported quarter, Q2 2026, shows $571.7M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗